Fred brings close to 30 years of biotech, pharmaceutical, and medical device experience to Alexion, where he oversees strategy and business development activities. Prior to joining Alexion, he served as president and chief executive officer of LogicBio. Previously, Fred served as the president and chief operating officer of aTyr Pharma Inc. He also served as president and chief executive officer of Pervasis Therapeutics until its acquisition by Shire Pharmaceuticals where he had a critical impact on the development of the hereditary angioedema (HAE) franchise. Earlier in his career, for nearly a decade, Fred served in various roles at Genzyme including vice president and general manager of the Cardiovascular Business Unit, and held sales and marketing roles with a medical device company in France. He is also a member of the Board of Directors for Coave Therapeutics. Fred holds a B.S. in physics from Paris University, a M.S. from ESC La Rochelle and an MBA from INSEAD.